News

ASH President Alexis Thompson, MD, MPH, responds to the White House's FY2019 budget request, which includes funding for the opioid crisis and supports regenerative medicine techniques like genome editing.
Read more on American Society of Hematology »
Today, Congress agreed to a two-year budget deal that will raise spending caps for non-defense discretionary programs, including the National Institutes of Health.
Read more on American Society of Hematology »
Researchers have demonstrated the design and synthesis of a smart globular macromolecular machine vehicle for actively controlled cancer drug delivery, which would enhance the drug's efficacy.
Read more on Science Daily »
Researchers have identified two gene regions that contribute to multiple myeloma, an inherited cancer that occurs in bone marrow, through a new method that makes use of human disease pedigrees.
Read more on Science Daily »
Injecting minute amounts of two immune-stimulating agents directly into solid tumors in mice can eliminate all traces of cancer in the animals, including distant, untreated metastases, according to a new study.
Read more on Science Daily »
A new anti-cancer strategy wields light as a precision weapon. Unlike traditional light therapy -- which is limited to the skin and areas accessible with an endoscope -- this technique can target and attack cancer cells that have spread deep…
Read more on Science Daily »
ASH President Alexis A. Thompson, MD, MPH, outlined the Society's priorities in working with the US Department of Health and Human Services under newly-confirmed Secretary Alex Azar in this statement.
Read more on American Society of Hematology »
Researchers have discovered an unknown biological process that controls the production of vital cells that carry oxygen throughout the body. The discovery could help doctors develop new treatments for anemias that affect millions of people.
Read more on Science Daily »
Laura C. Michaelis, MD, has been named Editor-in-Chief of The Hematologist: ASH News and Reports, the official member news magazine of the American Society of Hematology (ASH), serving through 2020.
Read more on American Society of Hematology »
Patients with monoclonal gammopathy of undetermined significance are at risk of progressing to multiple myeloma or a related cancer even after 30 years of stability.
Read more on Science Daily »
ASH is pleased to announce that Melody Smith, MD, of Memorial Sloan Kettering Cancer Center and Allistair Abraham, MD, of Children’s National Health System have been selected to participate in the ASH-Harold Amos Medical Faculty Development Program (ASH-AMFDP).
Read more on American Society of Hematology »
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists have now found…
Read more on Science Daily »
A research team has validated a way to outfox tumors. They engineered T-cells, essential players in the body's own immune system, to strip tumors of their self-preservation skill and were able to hold Hodgkin lymphoma at bay in patients with…
Read more on Science Daily »
Scientists use enzymes responsible for marine animal bioluminescence to help researchers test whether cancer immunotherapies work.
Read more on Science Daily »
Researchers have figured out a way to prevent MYB, one of the most potent cancer-aiding proteins, from activating genes in AML, an aggressive form of leukemia. Tested in mice, the new method resulted in dramatic cancer reduction and no harm…
Read more on Science Daily »
A new study has found germline variations in a key tumor suppressor gene that may prompt changes in treatment and follow-up care for certain high-risk leukemia patients.
Read more on Science Daily »
Alexis A. Thompson, MD, MPH, a world-renowned expert in sickle cell disease and thalassemia, will serve as president of the American Society of Hematology for a year-long term through December 2018.
Read more on American Society of Hematology »
The proteasome inhibitor carfilzomib has taken on an increasing role in the treatment of multiple myeloma, but new research shows the therapy comes with the risk of cardiovascular problems in a higher than expected percentage of patients.
Read more on Science Daily »